LEPU BIO-B: Meiyouheng® (Injection Vabecotuzumab) for the treatment of R/M NPC approved for market launch
I'm PortAI, I can summarize articles.
LEPU BIO-B announced that its self-developed EGFR-targeted antibody drug Meiyouheng® (injection of Vebekotamab) has been approved by the National Medical Products Administration for marketing in China. This drug is used for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) and is the first EGFR-targeted ADC approved in the country, marking an important milestone for the company. The company plans to further expand the indications of this drug based on this approval to enhance its commercial value
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments